A DNA-Based Nanocarrier for Efficient Gene Delivery and Combined Cancer Therapy

The efficient delivery of a therapeutic gene into target tissues has remained a major obstacle in realizing a viable gene-based medicine. Herein, we introduce a facile and universal strategy to construct a DNA nanostructure-based codelivery system containing a linear tumor therapeutic gene (p53) and...

Full description

Saved in:
Bibliographic Details
Published in:Nano letters 2018-06, Vol.18 (6), p.3328-3334
Main Authors: Liu, Jianbing, Song, Linlin, Liu, Shaoli, Jiang, Qiao, Liu, Qing, Li, Na, Wang, Zhen-Gang, Ding, Baoquan
Format: Article
Language:English
Subjects:
Animals
Antibiotics, Antineoplastic - administration & dosage
Antibiotics, Antineoplastic - therapeutic use
Cell Line, Tumor
DNA - chemistry
Doxorubicin - administration & dosage
Doxorubicin - therapeutic use
Drug Carriers - chemistry
Drug Delivery Systems - methods
Gene Transfer Techniques
Genes, p53
Genetic Therapy - methods
Humans
Mice, Nude
Nanomedicine - methods
Nanostructures - chemistry
Neoplasms - genetics
Neoplasms - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The efficient delivery of a therapeutic gene into target tissues has remained a major obstacle in realizing a viable gene-based medicine. Herein, we introduce a facile and universal strategy to construct a DNA nanostructure-based codelivery system containing a linear tumor therapeutic gene (p53) and a chemotherapeutic drug (doxorubicin, DOX) for combined therapy of multidrug resistant tumor (MCF-7R). This novel codelivery system, which is structurally similar to a kite, is rationally designed to contain multiple functional groups for the targeted delivery and controlled release of the therapeutic cargoes. The self-assembled DNA nanokite achieves efficient gene delivery and exhibits effective inhibition of tumor growth in vitro and in vivo without apparent systemic toxicity. These structurally and chemically well-defined codelivery nanovectors provide a new platform for the development of gene therapeutics for not only cancer but also a wide range of diseases.
ISSN:1530-6984
1530-6992
DOI:10.1021/acs.nanolett.7b04812